SIRT1 and metabolic syndrome: In addition, despite that simvastatin treatment ameliorates the augmented leptin expression in RVLM and that high level leptin inhibits AMPK phosphorylation [62], there is no evidence from the current study for an active role of simvastatin-regulated AMPK-SIRT1 signal in RVLM on dyslipidemia and hyperleptinemia manifested in HFD offspring.